Cormorant Buys $8M More of Alumis After 400% Rally
0h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
alumis
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Cormorant Asset Management acquired an additional $8 million worth of Alumis Inc. stock during the first quarter of 2026, according to a 13F filing published on May 17. This purchase occurred after the clinical-stage biotech’s shares had already appreciated by approximately 400% from their July 2024 initial public offering price. The firm’s increased position highlights a significant vote of confidence from a sophisticated healthcare investor amid extreme volatility.
Biotechnology stocks are highly sensitive to clinical trial data and regulatory catalysts. The sector, as tracked by the SPDR S&P Biotech ETF (XBI), has gained 15% year-to-date, outperforming the broader S&P 500's 8% rise. This outperformance is partly driven by a renewed risk-on appetite as interest rate expectations have stabilized.
The catalyst for Alumis’s dramatic revaluation was the January 2026 announcement of positive Phase 2b topline data for ESK-001, its lead candidate for moderate-to-severe plaque psoriasis. The data demonstrated statistically significant improvement over placebo, positioning ESK-001 as a potential best-in-class oral therapy. This successful data readout was the pivotal event that transformed the stock from a speculative bet into a credible late-stage company.
Cormorant’s latest acquisition brings its total disclosed holdings in Alumis to over 1.2 million shares, with a market value exceeding $45 million based on recent prices. The stock closed at $38.22 on May 16, down 12% from its post-data peak of $43.50 in February but still vastly above its $7 IPO price. The company’s market capitalization now stands at approximately $1.8 billion.
Trading volume has remained elevated, averaging over 1.5 million shares daily since the data release, compared to a pre-data average of under 200,000 shares. This heightened activity indicates sustained institutional interest and liquidity. Alumis’s volatility is substantially higher than the biotech sector average, reflecting its binary dependence on a single asset.
| Metric | Pre-Data (Jan 2026) | Post-Data (May 2026) | Change |
|---|---|---|---|
| Share Price | ~$9.50 | $38.22 | +302% |
| Market Cap | ~$450M | ~$1.8B | +300% |
| Avg. Daily Volume | 180,000 | 1.5M | +733% |
Cormorant’s aggressive buying suggests the firm believes the market is still undervaluing ESK-001’s commercial potential, particularly for its second indication in systemic lupus erythematosus. This activity can create a halo effect for other companies developing oral inflammatory therapies, such as AnaptysBio (ANAB) and Ventyx Biosciences (VTYX), whose shares are up 8% and 5% respectively over the past month.
The primary counter-argument is Alumis’s concentrated risk profile. The company’s entire valuation is predicated on the success of one drug. Any clinical, regulatory, or commercial setback for ESK-001 would likely trigger a severe correction. Despite the recent pullback, short interest remains elevated at 15% of the float, indicating a sizable cohort of investors betting against further gains.
Positioning data shows institutional ownership has climbed from 40% at IPO to over 70% currently, with several other healthcare-focused funds establishing new positions alongside Cormorant. Flow has been overwhelmingly bullish, though profit-taking from early investors has provided selling pressure.
The next major catalyst for Alumis is the initiation of Phase 3 trials for ESK-001 in psoriasis, expected to be announced by the third quarter of 2026. Investors will scrutinize the trial design and any partnership announcements for the global program. Data from an ongoing Phase 2 trial in lupus is expected in the first half of 2027.
Key technical levels to monitor include the 50-day moving average near $36, which has acted as recent support. A sustained break below this level could signal a deeper retracement toward the $30 zone. Conversely, a move above the February high of $43.50 would require a significant new catalyst and could indicate the next leg up.
The company’s cash burn rate will be a focal point in upcoming earnings reports. With a current cash position of approximately $300 million, the market will assess if existing funds are sufficient to fund Phase 3 development or if a dilutive financing event is likely.
Alumis stock surged over 400% primarily due to positive Phase 2b clinical trial data for its lead drug, ESK-001, in plaque psoriasis. The data demonstrated strong efficacy and a favorable safety profile, significantly de-risking the asset's path to market and increasing its estimated commercial potential. This caused a rapid reassessment of the company's valuation by the market.
Cormorant Asset Management is a Boston-based hedge fund specializing in public and private healthcare investments. The firm is known for its concentrated, high-conviction bets on emerging biotechnology companies with disruptive science. Its portfolio often includes companies with novel drug platforms or therapies addressing unmet medical needs in specialty markets.
Positive Phase 3 trial results typically cause substantial stock appreciation as they are the final step before regulatory submission for approval. However, they also carry high risk; failure in Phase 3 often results in declines of 50-80% as years of development costs are written off. Success can lead to buyout interest from larger pharmaceutical companies.
Cormorant's $8 million bet signals deep conviction that Alumis's recent 400% rally undervalues its lead drug's blockbuster potential.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.